Court Denies Renovaro Motion for an Expedited Trial in July
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Court Denies Renovaro Motion for an Expedited Trial in July
May 27, 2025 8:35 AM EDTPITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.
Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENBs request for an expedited, two-day trial in July. The Court reached this decision citing RENBs delay in bringing its action.Â
POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premised on inaccurate allegations and lack any merit. The... More
